Home » drug developer

drug developer

Jan 20, 2016

Elsevier Continues Focus on Pharmacovigilance, Updates Sequence Analysis Software

Premium

The company is working on a bespoke pharmacovigilance product that will leverage its biomedical content, and has added an NGS module to Pathway Studio. 

Jan 05, 2016

Sanofi Partners With Global Genomics Group on Cardiovascular Diseases

The collaboration will focus on identifying new signaling pathways and targets involved in coronary artery disease.

Jan 05, 2016

More Drugs Approved in 2015

The Associated Press reports that the US Food and Drug Administration approved 45 new drugs last year.

Oct 26, 2015

CRISPR Therapeutics, Vertex Pharmaceuticals Ink $105M Collaboration Deal

The partners will focus on developing gene editing-based treatments for cystic fibrosis and sickle cell disease, among other diseases.

Jun 29, 2015

Study Shows Genetic Support for Drug Targets Could Double Clinical Development Success Rate

Therapies aimed at drug targets that have been linked genetically to disease fare better through the drug development pipeline, researchers from GSK and elsewhere found.

Jun 17, 2015

AMRI, PerkinElmer to Collaborate on Drug Discovery

The partners will provide drug discovery services, expertise, and infrastructure in a new AMRI center located in the Buffalo Medical Innovation and Commercialization Hub.

Mar 03, 2015

Blueprint Medicines Inks Deal with Alexion Targeting Rare Genetic Disease

The partners will develop novel drug candidates based on an activated kinase target for an unnamed rare genetic disease.

Apr 02, 2009

Genesis Says Its Future Is Uncertain in Face of Limited Funding, Partnership Options

Premium

The New Zealand firm, which is "evaluating all options," has also been unable to secure the more than $1 million it is owed for selling its stake in a biofuels shop, or to find funding from a government technology-investment group.

Apr 02, 2009

MDRNA Sells Manufacturing Business to Par Pharmaceuticals to Hone RNAi Focus

Premium

The agreement, which eliminates all of MDRNA's non-RNAi expenses, "represents the final step in our plan to create a company solely focused in the research and development of RNAi-based therapeutics," Michael French, president and CEO of MDRNA, said in a statement.

Mar 12, 2009

MDRNA Aims to Stay on Nasdaq Global Market, Arrowhead Shifts Shares to Capital Market

Premium

Both companies failed to meet the Nasdaq Global Market's minimum shareholder listing requirement. But while MDRNA aims to keep its shares remain on the exchange's top tier, Arrowhead instead requested its stock be moved to the Capital Market, where the listing requirements are less stringent.

Pages

The Scan

No More

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

Dunno What Those Do

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

HeLa Variety

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

This Week in Nature

In Nature this week: protein-coding variants associated with body-fat distribution, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.